NEW YORK CITY, NY / ACCESS Newswire / June 4, 2026 / Lifshitz Law Firm
Picard Medical, Inc. (NYSE:PMI)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (ii) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (iii) Picard's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.
If you are a PMI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Ardent Health, Inc. (NYSE:ARDT)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Ardent Health's third quarter 2025 revenue was overstated due to inadequate determinations of accounts receivable collectability following the Company's transition to a new revenue accounting system and "recently completed hindsight evaluations of historical collection trends"; (ii) the Company's 2025 EBITDA guidance was overstated and would be reduced by $57.5 million at the midpoint, or approximately 9.6%, due to "persistent industry-wide cost pressures," including "payer denials"; and (iii) as a result, the Company's statements about Ardent Health's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you are an ARDT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the Company provided overwhelmingly positive statements to investors regarding the development and prospects of fasedienol, despite the fact that the Company's Phase 3 PALISADEâ?'3 trial of the investigational pherine candidate for the acute treatment of social anxiety disorder was beset by materially adverse facts; (ii) the Company disseminated false and misleading information and/or concealed material adverse data concerning the PALISADEâ?'3 study's design, execution, and clinical results; and (iii) as a result, the Company's statements about Vistagen's business, operations, and prospects were materially false and misleading at all relevant times.
If you are a VTGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Integer Holdings Corporation (NYSE:ITGR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) integer materially overstated its competitive position within the growing electrophysiology ("EP") manufacturing market; (ii) despite Integer's claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (iii) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company's C&V segment; and (iv) as a result of the foregoing, the Company's positive statements about Integer's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you are an ITGR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2026 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516) 493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@lifshitzlaw.com
SOURCE: Lifshitz Law Firm
View the original press release on ACCESS Newswire
COMTEX_482933505/2457/2026-06-04T12:12:30